Reynolds Cameron John
Company insiders · President and CEO · Director · VOLITIONRX LTD
- Reported transaction lines
- 1
- Buy lines
- 1
- Sell lines
- 0
Filing activity by month
Original filing lines in up to 12 months with activity.
- 2026-111
Frequently disclosed stocks
Disclosure history
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source |
|---|---|---|---|---|---|---|
| Reynolds Cameron John President and CEO · Director · VOLITIONRX LTD | VNRX VOLITIONRX LTD | BuyFiling detailsSEC transaction code P Common Stock · Direct ownership · Reported balance after transaction: 185781 · SEC code covers open-market or private transactions · On April 28, 2026, the Issuer effected a one-for-20 reverse stock split of its issued and outstanding common stock and made proportionate retroactive adjustments to its outstanding equity awards to the extent required including with respect to then-outstanding RSUs (the "Reverse Split"). No fractional shares were issued in connection with the Reverse Split, and each holder who otherwise would have been entitled to receive a fractional share received one whole share of common stock in lieu of such fractional share. Accordingly, the amount of securities beneficially owned directly and indirectly in column 5 of Table 1 has been adjusted to reflect the impact of the Reverse Split. | 2026-11-19 | 2026-11-20 | ≈ $6,848.00 40,000 shares/units | SEC 4 |
Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.